Big Pharma’s Challenge: Figuring out China

Sanofi-aventis can’t hire fast enough in China. The French drug giant has been paring its staff in the U.S. and Europe, but it is expanding its Chinese workforce by one-fifth every year and vying with other multinationals to recruit thousands of new sales representatives. These pitchmen, armed with information on Sanofi’s latest cardiovascular and diabetes drugs, will fan across the mainland in pursuit of untapped markets.

A Chinese stake in GM? Bravo!

The drumbeat in the blogosphere began about a millisecond after the news broke on Monday that Shanghai Automotive Industrial Corp. was considering buying a piece of General Motors when the US Treasury Department floats its shares in an IPO sometime later this year. „The U.S. government should block such a deal from ever occurring,” wrote one outraged commentator at Yahoo News. „Major U.S. companies like GM should be owned by American investors, not by any company run by a foreign government; particularly a foreign government that is hostile toward the U.S. This deal would jeopardize U.S. national security and should be rejected.”

Four companies facing the China squeeze

Many large U.S. companies have been forced to get creative in order to boost profits as demand for their products and services has slowed along with the economy. Now some of them have another battle looming: China’s plan to temper growth in its plan of attack to avoid inflation.